Freespira is the only FDA-cleared treatment proven to reduce or eliminate panic attacks and post-traumatic stress disorder (PTSD) symptoms. Unlike medication or talk therapy, in 28 days Freespira addresses underlying breathing irregularities common in individuals suffering from these debilitating conditions.

Cognoa is developing digital products intended to support healthcare providers in expediting diagnosis with the goal of improving access to timely intervention for children and families, starting with autism spectrum disorder (ASD).

We are developing digital diagnostic and therapeutic products with the goal of enabling earlier and more equitable care for behavioral health conditions.

Unlike medication or talk therapy, Freespira teaches you to regulate your breathing patterns. That’s because breathing differences, and hypersensitivity to CO2, are often linked with panic and PTSD symptoms.

Cognoa seeks to help improve the lives and outcomes of children and their families living with behavioral health conditions. We strive to improve timely, equitable access to a diagnosis for caregivers with early concerns of developmental delay, including autism, to support opportunities for early intervention and improved outcomes for children and their families.